Secondary Logo

Most Popular Articles

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies

Weiss, Catherine; Weiller, Emmanuelle; Baker, Ross A.; More

International Clinical Psychopharmacology. 33(5):255-260, September 2018.

Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate

Montalvo, Itziar; Ortega, Laura; López, Xavi; More

International Clinical Psychopharmacology. 28(1):46-49, January 2013.

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

Boulenger, Jean-Philippe; Loft, Henrik; Olsen, Christina Kurre

International Clinical Psychopharmacology. 29(3):138-149, May 2014.

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

Jacobsen, Paula L.; Harper, Linda; Chrones, Lambros; More

International Clinical Psychopharmacology. 30(5):255-264, September 2015.

Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder

Fineberg, Naomi A.; Baldwin, David S.; Drummond, Lynne M.; More

International Clinical Psychopharmacology. 33(6):334-348, November 2018.

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union

Brody, Robert S.; Liss, Charles L.; Wray, Heather; More

International Clinical Psychopharmacology. 33(2):59-65, March 2018.

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Earley, Willie; Durgam, Suresh; Lu, Kaifeng; More

International Clinical Psychopharmacology. 32(6):319-328, November 2017.

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia

Singh, Arun; Gopal, Srihari; Kim, Edward; More

International Clinical Psychopharmacology. 33(4):213-216, July 2018.

Patient adherence and efficacy of quetiapine treatment in schizophrenia: results of a multicentre, naturalistic 6-month follow-up study

Alptekin, Koksal; Aydin, Hamdullah; Gucer, Kadri M.; More

International Clinical Psychopharmacology. 25(6):342-348, November 2010.

Evaluation of naltrexone for dissociative symptoms in borderline personality disorder

Schmahl, Christian; Kleindienst, Nikolaus; Limberger, Matthias; More

International Clinical Psychopharmacology. 27(1):61-68, January 2012.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy

Thase, Michael E.; Montgomery, Stuart; Papakostas, George I.; More

International Clinical Psychopharmacology. 28(3):113-120, May 2013.

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study

Montgomery, Stuart A.; Mansuy, Lucilla; Ruth, Adam C.; More

International Clinical Psychopharmacology. 29(1):26-35, January 2014.

Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics

Kwon, Jun Soo; Kim, Sung Nyun; Han, Jaewook; More

International Clinical Psychopharmacology. 30(6):320-328, November 2015.

Show: